Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 3Ganglioneuroblastoma 3Wilms Tumor 1Testicular Neoplasms 1Teratoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Germ Cell Cancer 1Endodermal Sinus Tumor 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 9Vincristine 8Dactinomycin 8Cyclophosphamide 8Ifosfamide 6Radiation 5Filgrastim 5Doxorubicin 5Irinotecan 4sargramostim 3pegfilgrastim 2brostallicin 2Vinorelbine 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Granulocyte Colony-Stimulating Factor 2Biopsy 2trioctyl phosphine oxide 1perifosine 1lorvotuzumab mertansine 1irinotecan sucrosofate 1imetelstat 1exatecan 1etoposide phosphate 1X-Rays 1Trabectedin 1Topotecan 1Surgical Procedures, Operative 1Spinal Puncture 1Sentinel Lymph Node Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Rhabdomyosarcoma × Congresses as Topic × Clear all
NCT00075582 2021-11-19

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Completed
390 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡